Natixis Advisors LLC Has $163.33 Million Stock Position in Sanofi (NASDAQ:SNY)

Natixis Advisors LLC raised its stake in Sanofi (NASDAQ:SNY) by 1.2% in the 1st quarter, HoldingsChannel reports. The fund owned 2,944,985 shares of the company’s stock after buying an additional 34,964 shares during the quarter. Natixis Advisors LLC’s holdings in Sanofi were worth $163,329,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of SNY. Cardinal Capital Management lifted its holdings in Sanofi by 0.3% in the first quarter. Cardinal Capital Management now owns 69,004 shares of the company’s stock valued at $3,827,000 after buying an additional 199 shares during the period. Gradient Investments LLC grew its stake in shares of Sanofi by 2.1% during the first quarter. Gradient Investments LLC now owns 9,764 shares of the company’s stock worth $542,000 after purchasing an additional 200 shares during the period. Perigon Wealth Management LLC increased its holdings in Sanofi by 3.1% in the first quarter. Perigon Wealth Management LLC now owns 6,618 shares of the company’s stock valued at $367,000 after purchasing an additional 201 shares during the last quarter. Beacon Financial Group lifted its stake in Sanofi by 1.6% in the first quarter. Beacon Financial Group now owns 14,398 shares of the company’s stock valued at $799,000 after buying an additional 222 shares during the period. Finally, AdvisorNet Financial Inc boosted its holdings in Sanofi by 16.4% during the first quarter. AdvisorNet Financial Inc now owns 1,613 shares of the company’s stock worth $89,000 after buying an additional 227 shares during the last quarter. 14.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on SNY. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Morgan Stanley set a $56.00 price target on shares of Sanofi in a report on Monday, June 2nd. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Hsbc Global Res upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 28th. Finally, BNP Paribas assumed coverage on shares of Sanofi in a research note on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $62.00.

Sanofi Stock Performance

NASDAQ SNY opened at $49.35 on Wednesday. Sanofi has a 52-week low of $45.80 and a 52-week high of $60.12. The stock has a market cap of $121.03 billion, a PE ratio of 17.63, a P/E/G ratio of 1.13 and a beta of 0.48. The firm has a 50-day moving average of $49.42 and a 200-day moving average of $52.13. The company has a debt-to-equity ratio of 0.16, a quick ratio of 0.69 and a current ratio of 1.37.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.